On-Demand Webinar: Avoiding Common Pitfalls in the IND and CTA Submission Process

Abstract: When planning an Investigational New Drug (IND) or Clinical Trial Authorization (CTA) submissionnavigating FDA, EMA, and other regulations can be challenging and creating scientifically-sound strategies are essentialAs submissions expand to multiple countries during later phase trials, greater challenges can arise if not prepared with knowledge of the requirements, proper time management, and defined roles for the team towards approval. 

Join us as experts in project management, medical writing, and regulatory operations discuss best practices for a successful submission process from start to finish. 

Attendees will learn:

  • Efficiencies for multi-country submissions 
  • Essential steps in pre-submission planning 
  • Timeline management and potential pitfalls 
  • How to define roles and responsibilities to avoid delays or confusion 
  • Structure and content of the submissions at various stages of development 
  • Navigating the countryspecific regulatory requirements 
  • Post-submission maintenance and responsibilities 

Presenters:

Jessica Reed, PhD, Senior ManagerProject and Account Management  

Nicole Northrop, PhD, Manager, Regulatory and Medical Writing 

Allison Ward, MSA, MSEd, Senior Manager, Regulatory Operations 

Avoiding Common Pitfalls in the IND and CTA Submission Process
Fill out the form below to view the webinar.
 
 

Read On

Protocol Writing: The Influence of Statistics on a Positive Outcome - MMS Holdings

In 2017, TransCelerate Biopharma released the latest version of the Common Protocol Template (CPT)...

The 505(b)(2) Submission & Early Planning - MMS Holdings Holdings

by Ben Kaspar, Director of Regulatory Affairs

Medical writing future, people, and processes | MMS Holdings

by Teresa Ceseña, Senior Director or Regulatory and Medical Writing